Generate Biomedicines (NASDAQ:GENB) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a report released on Tuesday morning, Marketbeat reports. The brokerage issued an overweight rating on the stock.

Separately, Wall Street Zen upgraded Generate Biomedicines to a “hold” rating in a research report on Saturday, March 14th. Five analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $25.00.

Generate Biomedicines Stock Performance

Shares of NASDAQ GENB opened at $12.85 on Tuesday. Generate Biomedicines has a 12-month low of $11.00 and a 12-month high of $15.32.

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.